|Assessment Status||Rapid Review Complete|
|Indication||Indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.|
|Rapid review commissioned||14/03/2023|
|Rapid review completed||31/03/2023|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that relugolix not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.